All of this talk about AstraZeneca reminds me of Gloria.Were you here when she said that AZ was our partner.The deal later fell apart at the last minute.So who knows.

This is what Hakan said about the almost partnership in an article by Charles Proctor....


Potential partner

However, this summer investors were optimistic. In May, the company announced that the FDA had accepted Afresa for review, and in June it said talks had started with a potential marketing partner. MannKind shares hit an 18-month high of $12.30 in July, not long after trading as low as $1.83 in April.

In fact, talks with the potential partner progressed to the point where the two sides were drawing up a contract, Edstrom said. He declined to name the company, but said it was a significant pharmaceutical firm with worldwide operations.

However, the two sides could not agree on the marketing potential for Afresa. MannKind projects the drug could have $2 billion in annual sales in the United States, but the potential partner set its projections lower. MannKind agreed to the lower projections, but demanded a higher cut of the revenue if Afresa exceeded them, Edstrom said.

That proved to be a roadblock neither company could clear. The two sides then agreed to postpone further negotiations until after the FDA approves the drug.

"We certainly parted as friends," said Edstrom, who added that MannKind would consider bids from multiple potential partners if Afresa is approved.

He said other potential marketing partners had approached MannKind, but that they wanted to wait for Afresa to secure FDA approval before entering negotiations. With no other immediate partners in sight, MannKind conceded it would have to wait for FDA approval.

As for Amylin's drugs...

http://www.amylin.com/products/